Drug · CHEMBL469
KETOROLAC
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. KETOROLAC. Drugs and targets, record CHEMBL469. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL469
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PTGS1 | Cyclooxygenase | Cyclooxygenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5742 |
| PTGS2 | Cyclooxygenase | Cyclooxygenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5743 |
Source ChEMBL
Diseases48
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 48Source Open Targets
See all 48 diseasesTrials330
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01267864 | Valproate Versus Ketorolac Versus Metoclopramide | Phase 4 | 330 | 2018-06-04 | ketorolac | Its name | ClinicalTrials.gov |
| NCT03464461 | Dosing of Ketorolac in the Emergency Department | Phase 4 | 289 | 2024-11-05 | ketorolac | Its name | ClinicalTrials.gov |
| NCT00507026 | Efficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery | Phase 3 | 277 | 2021-10-29 | ketorolac | Its name | ClinicalTrials.gov |
| NCT00521456 | A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery | Phase 3 | 263 | 2009-10-01 | ketorolac | Its name | ClinicalTrials.gov |
| NCT00524264 | A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery | Phase 3 | 248 | 2009-10-01 | ketorolac | Its name | ClinicalTrials.gov |
| NCT02266433 | Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders | Phase 3 | 245 | 2020-11-02 | ketorolac | Its name | ClinicalTrials.gov |
| NCT02543801 | A Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip and Knee Arthroplasty | Phase 4 | 239 | 2019-10-18 | ketorolac | Its name | ClinicalTrials.gov |
| NCT05291598 | Meloxicam for Pain Management After Total Joint Arthroplasty (TJA) | Phase 3 | 223 | 2024-08-14 | ketorolac | Its name | ClinicalTrials.gov |
| NCT01806259 | Ketorolac in Breast Cancer Surgery | Phase 3 | 203 | 2020-01-18 | ketorolac | Its name | ClinicalTrials.gov |
| NCT01345162 | Assessment and Prevention of Acute Post-herniotomy Pain | Phase 4 | 200 | 2014-06-09 | ketorolac | Its name | ClinicalTrials.gov |
1 to 10 of 330
See all 330 trialsComparisons in its trials155
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm Receiving Dexamethasone Injection vs Arm Receiving Ketorolac Injection: deaths from any cause | 0 of 127 | 0 of 118 | 245 | NCT02266433 | Trial comparisons |
| Arm Receiving Dexamethasone Injection vs Arm Receiving Ketorolac Injection: serious adverse events | 0 of 127 | 0 of 118 | 245 | NCT02266433 | Trial comparisons |
| Ketorolac Group vs IV Meloxicam Group: Length of Stay as Measured by Same Day Discharges | 23 of 114 | 10 of 109 | 223 | NCT05291598 | Trial comparisons |
| Ketorolac Group vs IV Meloxicam Group: deaths from any cause | 0 of 114 | 0 of 109 | 223 | NCT05291598 | Trial comparisons |
| Ketorolac Group vs IV Meloxicam Group: serious adverse events | 0 of 114 | 0 of 109 | 223 | NCT05291598 | Trial comparisons |
| Ketorolac 30 mg vs NaCl 0.9% 3mL: Recurrence-free Survival | 80 of 96 | 96 of 107 | 203 | NCT01806259 | Trial comparisons |
| Ketorolac 30 mg vs NaCl 0.9% 3mL: Overall Survival | 93 of 96 | 105 of 107 | 203 | NCT01806259 | Trial comparisons |
| Ketorolac 30 mg vs NaCl 0.9% 3mL: serious adverse events | 8 of 96 | 7 of 107 | 203 | NCT01806259 | Trial comparisons |
| Ketorolac vs Acetaminophene + Tramadol: serious adverse events | 0 of 98 | 0 of 96 | 194 | NCT01345162 | Trial comparisons |
| Rectal Indomethacin vs IV Ketorolac: Post-ERCP Pancreatitis | 15 of 96 | 21 of 96 | 192 | NCT05664074 | Trial comparisons |
1 to 10 of 155
See all 155 comparisons in its trialsPapers from its trials125
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL469
GET https://conductscience.org/api/drugs/v1/CHEMBL469/diseases?page=2